8-K: Neogen Reports Q1 FY26 Results Amid Restructuring

Neogen Corporation announced first-quarter fiscal 2026 results, reporting a revenue decline and lower adjusted profitability, alongside a new CEO and restructuring efforts.

Summary

• Total revenues for the first quarter were $209.2 million, a decrease of 3.6% compared to $217.0 million in the prior year.
• Core revenue, excluding foreign currency impacts and divestitures/discontinued product lines, increased by 0.3%.
• Net income for the quarter was $36.3 million, or $0.17 per diluted share, significantly up from a net loss of $12.6 million in the prior-year period, primarily due to a non-cash gain on the sale of the Cleaners & Disinfectants business.
• Adjusted Net Income was $9.4 million, or $0.04 per diluted share, down from $14.4 million, or $0.07 per diluted share, in the prior-year period.
• Gross margin decreased to 45.4% from 48.4% in the prior year, mainly due to integration-related costs, lower revenue, and tariffs.
• Adjusted EBITDA was $35.5 million, with an Adjusted EBITDA Margin of 17.0%, down from $43.7 million and 20.1% in the prior-year period.
• The company completed the divestiture of its Cleaners & Disinfectants business and used the net proceeds to repay $100.0 million of debt.
• Mike Nassif was welcomed as Chief Executive Officer and President, effective August 11.
• Restructuring actions, including headcount reductions, were implemented at the end of September to optimize the cost base.
• Neogen reaffirmed its full-year fiscal 2026 outlook, projecting revenue between $820 million and $840 million and Adjusted EBITDA between $165 million and $175 million.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to declines in key operational metrics like revenue, adjusted net income, gross margin, and adjusted EBITDA. While net income was positive due to a one-time gain, underlying business performance shows challenges. The new CEO's strategic initiatives and reaffirmed full-year outlook provide some optimism for future improvement, but current results are weaker.

Positives

• Net income significantly increased to $36.3 million due to a non-cash gain on the sale of the Cleaners & Disinfectants business.
• Core revenue showed a slight increase of 0.3%, indicating underlying business stability despite overall revenue decline.
• The Animal Safety segment achieved a strong core revenue increase of 5.8%, driven by Animal Care & Other, Life Sciences, and Biosecurity product categories.
• The Genomics business returned to positive mid-single-digit core revenue growth, with solid performance in bovine and other markets.
• The company successfully divested its Cleaners & Disinfectants business and used the proceeds to repay $100.0 million of outstanding debt, strengthening its balance sheet.
• New CEO Mike Nassif brings a sharpened emphasis on commercial excellence, renewed innovation, and a leaner cost structure, with restructuring actions already underway.

Negatives

• Total revenues decreased by 3.6% to $209.2 million compared to the prior year.
• Adjusted Net Income declined to $9.4 million from $14.4 million, and Adjusted Earnings Per Share decreased to $0.04 from $0.07.
• Gross margin decreased to 45.4% from 48.4%, primarily due to integration-related costs, lower revenue, and tariffs.
• Adjusted EBITDA decreased to $35.5 million from $43.7 million, with the Adjusted EBITDA Margin falling to 17.0% from 20.1%.
• The Food Safety segment experienced a 4.6% revenue decrease and a 1.7% core revenue decline.
• Sales of Petrifilm declined due to channel inventory rebalancing related to switching distributors in Asia and normalization of buying patterns at a U.S. distributor.
• The Veterinary Instruments & Disposables product category saw lower revenue, mainly from a decline in sales of needles and syringes.
• Operating loss was reported at $16.091 million, compared to an operating income of $2.257 million in the prior year.

Risks

• Execution challenges have hampered recent performance, requiring a sharpened emphasis on commercial excellence and innovation.
• Integration-related costs, particularly associated with the relocated production of sample collection products, are impacting gross margin.
• The cost of tariffs is negatively affecting gross margin.
• Channel inventory rebalancing and normalization of buying patterns at distributors can lead to declines in product sales, as seen with Petrifilm.
• Forward-looking statements are subject to risks and uncertainties, and actual future results may differ materially from expectations.

Future Outlook

The company is reaffirming its full-year fiscal 2026 outlook, anticipating revenue in the range of $820 million to $840 million and Adjusted EBITDA between $165 million and $175 million. Capital expenditures are expected to total approximately $50 million.

Management Comments

• "I see tremendous opportunity ahead to leverage Neogen’s strong, longstanding leadership in food and animal safety."
• "Few companies are as well-positioned as we are to help shape a safer, healthier world through a dedicated focus on these important end markets."
• "Recent performance has been hampered by execution challenges which we are tackling head-on with a sharpened emphasis on commercial excellence, renewed innovation and a leaner cost structure."
• "We recently implemented company-wide cost initiatives, which included the difficult decision to reduce headcount across the organization."
• "With this disciplined approach, I’m confident we can deliver compelling innovation for our customers, significantly improved financial performance and a fulfilling experience for our dedicated workforce, creating a path to sustainable value creation for our shareholders."

Industry Context

Neogen operates in the critical food and animal safety markets, which are subject to ongoing demand for quality control, disease prevention, and genetic improvement. The company's strategic actions, including divestitures and cost restructuring, reflect a broader industry trend towards optimizing portfolios and improving operational efficiency in response to market pressures and competitive landscapes. The focus on 'commercial excellence' and 'renewed innovation' aligns with the need for companies in this sector to continuously adapt to evolving regulatory standards and technological advancements.

Comparison to Industry Standards

• NA

Management Changes

Stakeholder Impact

• Shareholders: Potential for sustainable value creation is highlighted by management, but current operational declines may impact short-term returns. The one-time gain on divestiture boosted reported net income.
• Employees: Restructuring actions included headcount reductions across the organization.
• Customers: The company aims to deliver compelling innovation and values customer solutions and expertise.
• Creditors: Repayment of $100.0 million of debt using divestiture proceeds improves the company's debt profile.

Next Steps

• Continue to implement company-wide cost initiatives and restructuring actions.
• Focus on commercial excellence and renewed innovation.
• Deliver compelling innovation for customers.
• Work towards significantly improved financial performance and sustainable value creation for shareholders.
• Host a conference call and webcast on October 9, 2025, at 8:00 a.m. Eastern Time to discuss financial results.

Key Dates

Recommendation

While the first-quarter operational results show declines in revenue, adjusted net income, gross margin, and adjusted EBITDA, the company has a new CEO who is implementing significant restructuring and cost-cutting measures. The one-time gain from the divestiture boosted reported net income, and the full-year outlook has been reaffirmed. This indicates a period of transition and strategic adjustment. A 'hold' recommendation is appropriate as investors await the impact of the new management's initiatives and a clearer picture of sustainable operational improvement, rather than reacting solely to the mixed Q1 results.

Keywords

Neogen, NEOG, Q1 2026 earnings, financial results, food safety, animal safety, adjusted EBITDA, revenue, net income, restructuring, debt repayment, divestiture, Mike Nassif, CEO, corporate governance